Centauri Therapeutics

Centauri Therapeutics is a clinical-stage immunotherapy company developing treatments for life-threatening infectious diseases using its proprietary platform.

The technology uses synthetic bifunctional molecules that recruit and redirect naturally occurring anti-glycan antibodies to target pathogens, engaging both innate and adaptive immune responses.

The company's lead programme, ABX-01, targets multidrug-resistant Gram-negative bacterial infections in vulnerable patients.

Centauri also has early proof-of-concept data supporting oncology applications of the platform.